News Releases
Apr 24, 2024
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting Read more
Apr 9, 2024
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) Read more
Mar 7, 2024
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Read more
Mar 5, 2024
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting Read more
Jan 3, 2024
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference Read more
Displaying 11 - 15 of 15